<table>
<thead>
<tr>
<th><strong>Mayo Clinic Minute: What is chimeric antigen receptor-T cell therapy?</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chimeric antigen receptor-T cell therapy, also known as CAR-T cell therapy, is a personalized treatment giving hope to patients diagnosed with various lymphomas.</td>
</tr>
</tbody>
</table>
| **Madiha Iqbal, M.B.B.S., M.D.**  
**Hematology/Oncology**  
**Mayo Clinic**  

"Lymphoma in plain terms is essentially a cancer of your immune system." |
| Dr. Madiha Iqbal, a Mayo Clinic hematologist and oncologist, says patients who are newly diagnosed with lymphoma are offered a combination of chemotherapy and antibody-based treatments.  
But for those patients who do not respond to two or more lines of such treatments, CAR-T cell therapy may be an option.  

"Prior to the advent of CAR-T cell therapy, patients who had failed two lines of chemotherapy had a very poor survival of around six months." |
| Receiving CAR-T cell therapy can take a few weeks as a patient's T cells, which normally help fight off infections, are collected and genetically engineered to target lymphoma.  
After a low-dose chemotherapy, the modified cells are infused back into the patient which can then attack and destroy the lymphoma.  

"Patients who had a very poor prognosis can now potentially be cured of their disease." |
| For the Mayo Clinic News Network, I'm Alex Osidadcz. |